RTS,S anti-malaria vaccine is more effective than expected, based on the results of the second phase of clinical trials. The development of this vaccine against malaria has been prolonged and studies carried out so far indicated an efficacy of 30%. However, the results of the second phase of clinical trials prior to launch indicate that this efficiency is greater than 50%.